Lv1
40 积分 2023-03-12 加入
OA13.02 Global Phase 2 Randomized Trial of BNT327 (Pumitamig; PD-L1 x VEGF-A bsAb) + Chemotherapy for 1L ES-SCLC: Dose Optimization Analysis
2个月前
已关闭
The promise of bispecific antibodies: Clinical applications and challenges
2个月前
已完结
Cell Granularity Reflects Immune Cell Function and Enables Selection of Lymphocytes with Superior Attributes for Immunotherapy
3个月前
已完结
Humanized Mouse Models for the Study of Infection and Pathogenesis of Human Viruses
3个月前
已完结
Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy
3个月前
已完结
First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study
3个月前
已完结
O-4 GEMSTONE-304: A phase 3 study of sugemalimab plus chemotherapy versus chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)
3个月前
已完结
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
3个月前
已完结
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
3个月前
已完结
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer
3个月前
已完结
皖公网安备34019202002308
